- Acquired by Smith & Nephew for $330M, Nov 2023
- Raised $15M Series G led by Bioventus, Jul 2020
- Raised $21M Series F, May 2017
About
CartiHeal develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal's cell-free, off-the-shelf implant, Agili-C, is CE marked for use in cartilage and osteochondral defects. Agili-C is a rigid, biphasic, biodegradable implant. The bone phase of the implant is composed of calcium carbonate in aragonite crystalline form, a well-known biomaterial that enhances bone formation. The cartilage phase is a composite of modified aragonite and hyaluronic acid. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle, and big toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In October 2020, the the Agili-C implant was granted breakthrough device designation by the US FDA.
Funding history · 7 rounds · $74.0M total
Q&A
- When was CartiHeal acquired and by whom?
- CartiHeal was acquired by Smith & Nephew in November 2023 for an amount of $330,000,000.
- What is CartiHeal's primary product?
- CartiHeal develops Agili-C, a cell-free, off-the-shelf implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints.
- What is the status of CartiHeal's Agili-C implant with the US FDA?
- In October 2020, CartiHeal's Agili-C implant was granted breakthrough device designation by the US FDA.
- How many employees does CartiHeal have?
- CartiHeal has 11-50 employees.
- What was CartiHeal's last funding round?
- CartiHeal's last funding round was a G Round in July 2020, with Bioventus as the lead investor.
- What is the total amount of funding CartiHeal raised?
- CartiHeal raised a total of $74,000,000 USD across all its funding rounds.
- Which investors participated in CartiHeal's F Round?
- The F Round in May 2017 included investments from Peregrine Ventures and Johnson & Johnson Innovation.
- Where is CartiHeal headquartered?
- CartiHeal is headquartered in Kefar Sava, Center District, Israel.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cartiheal.com |
|---|---|
| linkedin.com/company/1031481 |
Identifiers & details
| Founded | 2009-6 |
|---|---|
| Employees (exact) | 18 |
| Offices | Closter |
| Status reason | Acquired by Bioventus on May, 2022 |
Acquisitions & public offerings
Acquired by Smith & Nephew 2023-11 $330.0M
Radar intelligence
Patents
| EPO | 15 |
|---|
Publications (Crossref)
| Works | 4 |
|---|
Web history (Wayback)
| Domain | cartiheal.com |
|---|
Certificate / subdomain footprint
| Subdomains | 13 |
|---|